Hrabák J., Žemličková H., Bergerová T., Urbášková P.: Interpretation of the Susceptibility Test Results in Enterobacteria Producing 3rd- and 4th-Generation Cephalosporin- or Carbapenem-Hydrolyzing β-Lactamases
Authors:
J. Hrabák 1; H. Žemličková 2; T. Bergerová 1; P. Urbášková 2
Authors‘ workplace:
Ústav mikrobiologie, Lékařská fakulta UK a Fakultní nemocnice v Plzni
1; Národní referenční laboratoř pro antibiotika, Státní zdravotní ústav v Praze
2
Published in:
Epidemiol. Mikrobiol. Imunol. 60, 2011, č. 1, s. 4-9
Overview
The interpretation of the susceptibility of Gram-negative rods to β-lactams is currently under discussion in CLSI and EUCAST – two authorities on determination of clinical breakpoints. This article summarizes the current knowledge about clinical breakpoints in enterobacteria and proposes guidance for clinical microbiology laboratories in the Czech Republic.
Keywords:
ESBL – AmpC – carbapenemases – KPC – MBL – interpretation – breakpoint.
Sources
1. Ambler, R. P. The structure of ß-lactamases. Phil. Trans. R. Soc. Lond. Biol., 1980, 289, p. 321–331.
2. Bergerová, T., Hedlová, D., Jindrák, V., Urbášková, P. et al. Doporučený postup pro kontrolu výskytu kmenů Staphylococcus aureus rezistentních k xacilinu (MRSA) a s jinou nebezpečnou antibiotickou rezistencí ve zdravotnických zařízeních. Prakt. Lék., 2006, 86, s. 500–506. Dostupný na www: http://www.cls.cz/ dokumenty/dp_mrsa.doc
3. Bush, K., Jacoby, G. A., Medeiros, A. A. A functional classification scheme for ß-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother., 1995, 39, p. 1211–1233.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. CLSI Document M100-S-20, PA, USA, 2010.
5. Cornaglia, G., Akova, M., Amicosante, G., Cantón, R. et al. Metallo-ß-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int. J. Antimicrob. Agents, 2007, 29, p. 380–388.
6. Empel, J., Hrabák, J., Kozińska, A., Bergerová, T. et al. DHA-1-producing Klebsiella pneumoniae in a teaching hospital in the Czech Republic. Microb. Drug Res., 2010, 16, p. 291–295.
7. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1 April 2010. Dostupné na www: http://www.eucast.org
8. European Committee for Antimicrobial Susceptibility Testing (EUCAST) Determination of antimicrobial susceptibility test breakpoints. Clin. Microbiol. Infect., 2000, 6, p. 570–572.
9. Ho, P. L., Chan, W. M., Tsang, K. W., Wong, S. S. et al. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand. J. Infect. Dis., 2002, 34, p. 567–573.
10. Hrabák, J. Klinicky významné ß-laktamázy gramnegativních bakterií: širokospektré ß-laktamázy (ESBL). Epidemil. Mikrobiol. Imunol., 2007, 56, s. 103–111.
11. Hrabák, J. Klinicky významné ß-laktamázy gramnegativních bakterií: AmpC. Epidemiol. Mikrobiol. Imunol., 2007, 56, p. 155–165.
12. Hrabák, J., Empel, J., Bergerová, T., Fajfrlík, K. et al. International clones of Klebsiella pneumoniae and Escherichia coli with extended-spectrum ß-lactamases (ESBLs) in a Czech hospital. J. Clin. Microb., 2009, 47, p. 3353–3357.
13. Hrabák, J., Bergerová, T., Žemličková, H., Urbášková, P. Detekce širokospektrých ß-laktamáz (ESBL), ß-laktamáz AmpC, metalo-ß-laktamáz (MBL) a karbapenemáz KPC u gramnegativních tyček. Zprávy CEM, 2009, 18, s. 100–106.
14. Hrabák, J., Fridrichová, M., Štolbová, M., Bergerová, T. et al. First identification of metallo-beta--lactamase-producing Pseudomonas aeruginosa in the Czech Republic. Euro Surveillance, 2009, 14, p. 19102.
15. Hrabák, J., Chudáčková, E. Rezistence enterobakterií ke karbapenemům. Epidemiol. Mikrobiol. Imunol., 2008, 57, p. 125–136.
16. Hrabák, J., Vaniš, V., Bergerová, T., Urbášková, P. Průkaz ß-laktamáz širokého spektra (ESBL) a typu AmpC u enterobakterií. Zprávy CEM, 2007, 16, s. 31–36.
17. Chudáčková, E., Bergerová, T., Fajfrlík, K., Červená, D. et al. Carbapenem-non-susceptible strains of Klebsiella pneumoniae producing SHV-5 and/or DHA-1 ß-lactamases in a Czech hospital. FEMS Microbiol. Lett., 2010, v tisku.
18. Kim, Y. K., Pai, H., Lee, H. J., Park, S. E. et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob. Agents Chemother., 2002, 46, p. 1481–1491.
19. Leclercq, R., Cantón, R., Giske, C. et al. Expert rules in antimicrobial susceptibility testing. EUCAST, 2008. Dostupné na www: http://www.escmid.org/fileadmin/src/ media/PDFs/4ESCMID_Library/3Publications/ EUCAST _Documents/Other_Documents/EUCAST_Expert_rules_ final_April_20080407.pdf.
20. Miriagou, V., Cornaglia, G., Edelstein, M., Galani, I. et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin. Microbiol. Infect., 2010, 16, 112–122.
21. Pages, J. M., Lavigne, J. P., Leflon-Guibout, V., Marcon, E. et al. Efflux pump, the masked side of beta-lactam resistance in Klebsiella pneumoniae clinical isolates. PLoS One, 2009, p. e4817.
22. Pai, H., Kang, Ch.-I., Byeon, J.-H., Lee, K.-D. et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type- ß-lactamase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother., 2004, 48, p. 3720–3728.
23. Paterson, D. L., Bonomo, R. A. Extended-spectrum ß‑lactamases: a clinical update. Clin. Microb. Rev., 2005, 18, p. 657–686.
24. Paterson, D. L., Ko, W. C., Von Gottberg, A., Casellas, J. M. et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol., 2001, 39, p. 2206–2212.
25. Ramphal, R., Ambrose, P. G. Extended-spectrum ß‑lactamases and clinical outcomes: current data. Clin. Infect. Dis., 2006, 42, Suppl. 4, p. 1640–172.
26. Urbášková, P. Rezistence bakterií k antibiotikům. Vybrané metody. Praha: Trios, 1998.
27. Urbášková, P., Hrabák, J., Žemličková, H. Přirozené a získané ß-laktamázy AmpC: interpretace indukce, hyperprodukce a dereprese. Zprávy epidemiologie a mikrobiologie, 18, 2009, p. 209–211.
28. Weisenberg, S. A., Morgan, D. J., Espinal-Witter, R., Larone, D. H. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn. Microbiol. Infect. Dis., 2009, 64, p. 233–235.Do redakce došlo dne 00. 00. 2010.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2011 Issue 1
Most read in this issue
- Antibiotická rezistence Streptococcus pneumoniae a Streptococcus pyogenes v letech 1996–2009
- Bazovská S., Ďurovská J., Pancák J., Záborská M., Derdáková. M.: Lyme Borreliosis and Demyelinating Disease of the Central Nervous System
- Hrabák J., Žemličková H., Bergerová T., Urbášková P.: Interpretation of the Susceptibility Test Results in Enterobacteria Producing 3rd- and 4th-Generation Cephalosporin- or Carbapenem-Hydrolyzing β-Lactamases
- Kissová R., Maďarová L., Klement C.: Laboratory Diagnosis of Pandemic Influenza at the Department of Medical Microbiology of the Regional Authority of Public Health Based in Banská Bystrica in the Season 2009–2010